| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 30 | 2025 | 1538 | 3.030 |
Why?
|
| Genome-Wide Association Study | 23 | 2024 | 1828 | 2.900 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2023 | 2849 | 2.880 |
Why?
|
| Selection, Genetic | 6 | 2024 | 164 | 1.960 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2023 | 3351 | 1.950 |
Why?
|
| Genome, Human | 15 | 2020 | 1331 | 1.700 |
Why?
|
| Melanoma | 7 | 2024 | 951 | 1.660 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 897 | 1.640 |
Why?
|
| Mutation, Missense | 13 | 2024 | 935 | 1.510 |
Why?
|
| Codon, Nonsense | 3 | 2022 | 144 | 1.420 |
Why?
|
| Prostatic Neoplasms | 11 | 2017 | 1576 | 1.390 |
Why?
|
| Gene Expression Profiling | 12 | 2025 | 1882 | 1.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2025 | 2057 | 1.130 |
Why?
|
| Neoplasms | 7 | 2020 | 2957 | 1.060 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 697 | 1.040 |
Why?
|
| Genes, Neoplasm | 2 | 2019 | 86 | 0.950 |
Why?
|
| Gene Frequency | 6 | 2022 | 749 | 0.880 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 313 | 0.740 |
Why?
|
| X Chromosome | 1 | 2023 | 340 | 0.730 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 333 | 0.730 |
Why?
|
| Biomarkers, Tumor | 9 | 2025 | 1659 | 0.730 |
Why?
|
| Computational Biology | 6 | 2015 | 875 | 0.700 |
Why?
|
| Scleroderma, Systemic | 2 | 2019 | 124 | 0.690 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 200 | 0.690 |
Why?
|
| Biological Evolution | 5 | 2015 | 243 | 0.630 |
Why?
|
| Mutation | 8 | 2024 | 6228 | 0.600 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 368 | 0.600 |
Why?
|
| Genetic Variation | 6 | 2020 | 1580 | 0.600 |
Why?
|
| Humans | 76 | 2025 | 132089 | 0.580 |
Why?
|
| Models, Statistical | 3 | 2019 | 491 | 0.520 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2020 | 1044 | 0.520 |
Why?
|
| RNA Splicing | 3 | 2014 | 247 | 0.480 |
Why?
|
| Blood | 1 | 2015 | 102 | 0.470 |
Why?
|
| Genomics | 2 | 2014 | 1647 | 0.460 |
Why?
|
| Gene Expression | 2 | 2018 | 1558 | 0.460 |
Why?
|
| Exons | 4 | 2014 | 805 | 0.450 |
Why?
|
| Alleles | 5 | 2020 | 1686 | 0.450 |
Why?
|
| Genes, p53 | 2 | 2005 | 221 | 0.440 |
Why?
|
| Crossing Over, Genetic | 4 | 2001 | 55 | 0.440 |
Why?
|
| Carcinogenesis | 1 | 2017 | 359 | 0.420 |
Why?
|
| Logistic Models | 7 | 2022 | 1839 | 0.410 |
Why?
|
| Male | 51 | 2025 | 64967 | 0.400 |
Why?
|
| Introns | 1 | 2014 | 305 | 0.390 |
Why?
|
| Environmental Exposure | 1 | 2015 | 234 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 2018 | 147 | 0.370 |
Why?
|
| Algorithms | 5 | 2016 | 1722 | 0.370 |
Why?
|
| Meiosis | 7 | 2001 | 116 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2024 | 767 | 0.350 |
Why?
|
| Recombination, Genetic | 4 | 2001 | 441 | 0.350 |
Why?
|
| Cryptorchidism | 4 | 2012 | 37 | 0.350 |
Why?
|
| Lung | 4 | 2023 | 1559 | 0.350 |
Why?
|
| CpG Islands | 4 | 2023 | 343 | 0.340 |
Why?
|
| Case-Control Studies | 15 | 2024 | 3416 | 0.340 |
Why?
|
| Genotype | 14 | 2016 | 2697 | 0.340 |
Why?
|
| Receptors, Nicotinic | 5 | 2012 | 133 | 0.340 |
Why?
|
| Oncogenes | 2 | 2022 | 175 | 0.330 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 700 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 111 | 0.320 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 2648 | 0.310 |
Why?
|
| Genes, Essential | 1 | 2009 | 43 | 0.310 |
Why?
|
| Genetics, Population | 3 | 2017 | 188 | 0.310 |
Why?
|
| Disease | 1 | 2010 | 127 | 0.300 |
Why?
|
| Databases, Nucleic Acid | 2 | 2008 | 73 | 0.300 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1610 | 0.300 |
Why?
|
| DNA Methylation | 3 | 2024 | 1122 | 0.290 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 1362 | 0.280 |
Why?
|
| Chromosomes | 3 | 2000 | 139 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 41 | 0.270 |
Why?
|
| Smoking | 8 | 2024 | 940 | 0.260 |
Why?
|
| Organ Specificity | 2 | 2019 | 412 | 0.260 |
Why?
|
| Adenocarcinoma | 6 | 2020 | 1015 | 0.250 |
Why?
|
| Telomerase | 3 | 2019 | 168 | 0.250 |
Why?
|
| Homozygote | 4 | 2001 | 547 | 0.240 |
Why?
|
| Female | 33 | 2025 | 70695 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2019 | 1573 | 0.230 |
Why?
|
| Point Mutation | 1 | 2006 | 348 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 3011 | 0.220 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2010 | 305 | 0.210 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2003 | 16 | 0.210 |
Why?
|
| Heterozygote | 4 | 2020 | 713 | 0.200 |
Why?
|
| Odds Ratio | 3 | 2022 | 1254 | 0.190 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 291 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 408 | 0.190 |
Why?
|
| Homeodomain Proteins | 2 | 2002 | 575 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 409 | 0.190 |
Why?
|
| Prognosis | 10 | 2024 | 5014 | 0.190 |
Why?
|
| Nucleotides | 1 | 2022 | 89 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 1977 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2020 | 100 | 0.180 |
Why?
|
| Chromosome Mapping | 5 | 2012 | 1095 | 0.180 |
Why?
|
| Nigella sativa | 1 | 2020 | 1 | 0.170 |
Why?
|
| Trigonella | 1 | 2020 | 3 | 0.170 |
Why?
|
| Conserved Sequence | 1 | 2022 | 296 | 0.170 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 450 | 0.170 |
Why?
|
| Proteins | 3 | 2018 | 1035 | 0.170 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 24 | 0.170 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.170 |
Why?
|
| Risk Factors | 16 | 2020 | 10946 | 0.170 |
Why?
|
| Chromosome Inversion | 2 | 1991 | 78 | 0.170 |
Why?
|
| Open Reading Frames | 2 | 2014 | 218 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 613 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 197 | 0.160 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2019 | 32 | 0.160 |
Why?
|
| Genetic Association Studies | 2 | 2022 | 852 | 0.160 |
Why?
|
| Middle Aged | 21 | 2024 | 28998 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 1280 | 0.150 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 158 | 0.150 |
Why?
|
| Mammals | 1 | 2000 | 272 | 0.150 |
Why?
|
| Phylogeny | 2 | 2018 | 764 | 0.150 |
Why?
|
| Simuliidae | 1 | 2018 | 4 | 0.150 |
Why?
|
| Polytene Chromosomes | 1 | 2018 | 3 | 0.150 |
Why?
|
| Mucins | 1 | 2019 | 71 | 0.150 |
Why?
|
| Karyotype | 1 | 2018 | 30 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2018 | 72 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 761 | 0.140 |
Why?
|
| Aged | 16 | 2024 | 21438 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 1439 | 0.140 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 159 | 0.140 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 18 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 209 | 0.130 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 316 | 0.130 |
Why?
|
| Autoimmunity | 1 | 2018 | 182 | 0.130 |
Why?
|
| Linear Models | 1 | 2019 | 713 | 0.130 |
Why?
|
| Testis | 3 | 2012 | 422 | 0.130 |
Why?
|
| Karyotyping | 6 | 2000 | 317 | 0.130 |
Why?
|
| Finasteride | 1 | 2016 | 18 | 0.120 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 684 | 0.120 |
Why?
|
| Mice | 12 | 2012 | 18466 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2014 | 697 | 0.120 |
Why?
|
| Phenotype | 7 | 2018 | 4528 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 434 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2022 | 917 | 0.120 |
Why?
|
| Models, Genetic | 4 | 2008 | 771 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2012 | 32 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 811 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2016 | 359 | 0.110 |
Why?
|
| Animals | 17 | 2022 | 34798 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 625 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 262 | 0.110 |
Why?
|
| Inflammation | 2 | 2012 | 1519 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2438 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2007 | 363 | 0.100 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 5 | 0.100 |
Why?
|
| DNA Transposable Elements | 1 | 1993 | 188 | 0.090 |
Why?
|
| Life Style | 1 | 2015 | 453 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 310 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 142 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 223 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 360 | 0.090 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Animal Feed | 2 | 2022 | 79 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 177 | 0.090 |
Why?
|
| Chickens | 2 | 2022 | 302 | 0.090 |
Why?
|
| Software | 1 | 2016 | 732 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2012 | 430 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 21 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 221 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2016 | 523 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 89 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2092 | 0.080 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2010 | 88 | 0.080 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 109 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 2444 | 0.080 |
Why?
|
| beta Catenin | 1 | 2010 | 225 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 1131 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2010 | 212 | 0.070 |
Why?
|
| Genes, Overlapping | 1 | 2008 | 7 | 0.070 |
Why?
|
| Survival Rate | 2 | 2012 | 2194 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 57 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 719 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 166 | 0.070 |
Why?
|
| Disease Progression | 2 | 2013 | 2225 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 372 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1355 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7104 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4704 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2322 | 0.060 |
Why?
|
| Diet | 3 | 2022 | 1125 | 0.060 |
Why?
|
| Spermatocytes | 1 | 1986 | 24 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 632 | 0.060 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 72 | 0.060 |
Why?
|
| PAX6 Transcription Factor | 2 | 2002 | 38 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 444 | 0.060 |
Why?
|
| Paired Box Transcription Factors | 2 | 2002 | 75 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1168 | 0.060 |
Why?
|
| Adult | 8 | 2024 | 31575 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2002 | 1284 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2140 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 803 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 490 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2002 | 422 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 230 | 0.050 |
Why?
|
| Genetic Markers | 3 | 1993 | 617 | 0.050 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2004 | 19 | 0.050 |
Why?
|
| Eye Proteins | 2 | 2002 | 232 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 589 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 64 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3142 | 0.050 |
Why?
|
| Smokers | 1 | 2024 | 44 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 52 | 0.050 |
Why?
|
| Haplotypes | 3 | 2011 | 544 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1422 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 3770 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1444 | 0.050 |
Why?
|
| Mentha piperita | 1 | 2022 | 12 | 0.050 |
Why?
|
| Relaxin | 1 | 2002 | 14 | 0.050 |
Why?
|
| Prebiotics | 1 | 2022 | 28 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 252 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 116 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 288 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 636 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17416 | 0.040 |
Why?
|
| Gene Deletion | 3 | 2012 | 792 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 5168 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 811 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 409 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 1986 | 577 | 0.040 |
Why?
|
| Powders | 1 | 2020 | 24 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2002 | 812 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2012 | 247 | 0.040 |
Why?
|
| Eye | 1 | 2002 | 235 | 0.040 |
Why?
|
| Jews | 1 | 2020 | 34 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 153 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3681 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 624 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 742 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 493 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 439 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 541 | 0.040 |
Why?
|
| Black Sea | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 576 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2018 | 55 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 754 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 688 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1047 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 604 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2020 | 501 | 0.030 |
Why?
|
| Young Adult | 3 | 2018 | 9958 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 1280 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2022 | 995 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2020 | 684 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1719 | 0.030 |
Why?
|
| HapMap Project | 1 | 2016 | 13 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2674 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 385 | 0.030 |
Why?
|
| Transgenes | 2 | 2010 | 335 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 301 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 438 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 67 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 311 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 295 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3407 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 1991 | 140 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 698 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 322 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 321 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2013 | 454 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4754 | 0.020 |
Why?
|
| Texas | 2 | 2012 | 3629 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2016 | 519 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 795 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 317 | 0.020 |
Why?
|
| Sperm Count | 1 | 2012 | 91 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 21 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 131 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 31 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 34 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 440 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2002 | 380 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 622 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 448 | 0.020 |
Why?
|
| Muscle Development | 1 | 2010 | 73 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20560 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2016 | 699 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2002 | 764 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 946 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 313 | 0.020 |
Why?
|
| Actins | 1 | 2012 | 334 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2916 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 179 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1892 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 251 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 824 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1548 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2012 | 296 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2508 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 687 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 799 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 112 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2669 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 2393 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 475 | 0.020 |
Why?
|
| 11-Hydroxycorticosteroids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 611 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 1017 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 308 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1986 | 139 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1443 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 1035 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8549 | 0.010 |
Why?
|
| Registries | 1 | 2012 | 1581 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 2899 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5416 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1960 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13061 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 124 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2004 | 254 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 129 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 275 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 14749 | 0.010 |
Why?
|
| Glycine | 1 | 2002 | 161 | 0.010 |
Why?
|
| Plasmids | 1 | 2002 | 459 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 53 | 0.010 |
Why?
|
| Pigmentation | 1 | 2001 | 36 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1098 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 429 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 996 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 1077 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 651 | 0.010 |
Why?
|
| Infertility | 1 | 2001 | 81 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 13034 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2001 | 176 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 587 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 768 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 846 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1730 | 0.010 |
Why?
|
| Child | 1 | 2018 | 25786 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1473 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 4685 | 0.010 |
Why?
|
| Siberia | 1 | 1988 | 4 | 0.000 |
Why?
|
| Animals, Wild | 1 | 1988 | 29 | 0.000 |
Why?
|